Autoimmune and inflammatory disorder biologicals will power biotech market growth through to 2010

Biologicals designed to treat arthritis, immune and inflammatory disorders (AIID) are currently powering biotechnology market growth. Datamonitor's biotechnology strategic market analysis team has therefore analysed this market to identify key biological products, together with growth drivers a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of commercial biotechnology 2006-04, Vol.12 (3), p.237-241
Main Authors: Churchill, Clare A C, Belsey, Mark J
Format: Article
Language:English
Subjects:
Biological products
Biotechnology
Biotechnology industry
Crohn's disease
Drugs
Growth rate
Immunotherapy
Inflammatory diseases
Lupus
Market analysis
Monoclonal antibodies
Oncology
Pharmaceutical industry
Population
Proteins
Psoriasis
Psoriatic arthritis
Quality of life
Rheumatoid arthritis
Steroids
Studies
TNF inhibitors
Tumor necrosis factor-TNF
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Biologicals designed to treat arthritis, immune and inflammatory disorders (AIID) are currently powering biotechnology market growth. Datamonitor's biotechnology strategic market analysis team has therefore analysed this market to identify key biological products, together with growth drivers and resistors shaping the growth of this market. The AIID market covers a wide range of indications; however, the most prevalent are rheumatoid arthritis and psoriasis, which together represent a significant healthcare burden. A range of monoclonal antibody therapeutics such as Abbott/CAT's Humira are set to drive AIID biological market growth, together with Amgen/Wyeth's fusion protein Enbrel. Owing to very strong sales of Enbrel as a result of continued label expansion, Amgen is set to record the greatest biological AIID sales from 2004 to 2010. Many of the highly efficacious AIID biologicals such as Enbrel target TNF, which is rapidly emerging as the leading cytokine target for many AIID indications. Overall, AIID biologicals generated US$5.4bn in 2004, and this is set to rise to US$14.3bn by 2010: a strong compound annual growth rate of 17.9 per cent. [PUBLICATION ABSTRACT]
ISSN:1462-8732
1478-565X
DOI:10.1057/palgrave.jcb.3040172